Portola Pharmaceuticals
| Portola Pharmaceuticals | |
|---|---|
| legal form | Incorporated |
| founding | 2003 |
| Seat | San Francisco , CA USA |
| management | Scott Garland, CEO |
| Number of employees | 320 |
| sales | $ 40.1 million (2018) |
| Branch | pharmacy |
| Website | www.portola.com |
Portola Pharmaceuticals is an American biotechnological pharmaceutical company that was founded in Delaware in 2003 and is listed on the American technology exchange NASDAQ under the trademark PTLA. Headquartered has Portola in San Francisco , CA . The company specializes in the discovery, development and marketing of novel therapeutics in the areas of thrombosis and other haematological diseases.
Medication
Portola Pharmaceuticals has the following drugs in the market / in clinical development:
- Andexxa (USA) / Ondexxya (EU) ( Andexanet alfa ) is a recombinant coagulation factor Xa ; the first and only antidote ( antidote ) for patients treated with the new oral anticoagulants (Noaks) Rivaroxaban and apixaban be treated if a reversal of the anticoagulation is required due to life-threatening bleeding or uncontrolled. FDA approval for Andexxa was granted in May 2018. For Ondexxya (Andexanet alfa), the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) passed a positive recommendation for approval in the EU in February 2019. This recommendation was complied with at the end of April 2019, i.e. H. it was approved by the European Commission for the European member states.
- Bevyxxa ( Betrixaban ), the first and only oral once-daily factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. Betrixaban - like rivaroxaban and apixaban - belongs to the group of direct oral anticoagulants (DOAC), which are also known as new oral anticoagulants (NOAC). Bevyxxa is currently only approved in the USA.
- Cerdulatinib is still in clinical development: a Syk / JAK inhibitor for the treatment of haematological cancers.
Cooperations
Portola Pharmaceuticals cooperates with numerous international pharmaceutical companies, such as B. Bayer , Bristol-Myers Squibb , Daiichi-Sankyo , Janssen and Pfizer .
Web links
- WebSite of Portola Pharmaceuticals Inc.
- Portola Pharmaceuticals share
- DAZ: The first antidote for apixaban and rivaroxaban comes to Europe
- Pharmaceutical newspaper: Andexanet alfa stops heavy bleeding
Individual evidence
- ↑ a b c d e f FAQs , Company WebSite, accessed on April 27, 2019
- ↑ Executives , Company WebSite, accessed April 27, 2019
- ↑ Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update , PM Portola, March 1, 2019, accessed April 27, 2019
- ↑ Stock Quote , Company WebSite, accessed April 27, 2019
- ^ Corporate Profile , Company WebSite, accessed April 27, 2019
- ↑ a b European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxya ™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors , PM Portola, April 26, 2019, accessed April 29, 2019
- ↑ First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban , EMA PM on March 1, 2019, accessed on April 27, 2019.
- ↑ Accelerated approval for Antidot , Pharmazeutische Zeitung, March 1, 2019, accessed April 27, 2019
- ↑ Pipeline , Company WebSite, accessed April 27, 2019
- ↑ Collaborations , Company WebSite, accessed April 27, 2019